PHAS stock forecast
Our latest prediction for PhaseBio Pharmaceuticals, Inc.'s stock price was made on the July 1, 2019 when the stock price was at 13.88$.
In the short term (2weeks), PHAS's stock price should underperform the market by -1.57%. During that period the price should oscillate between -11.50% and +12.19%.
In the medium term (3months), PHAS's stock price should underperform the market by -1.69%. During that period the price should oscillate between -25.51% and +31.64%.Get email alerts
About PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -1.09$ per share.
The book value per share is 1.54$
Three months stock forecastJuly 1, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|